Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Non-Current Liabilities (2016 - 2026)

Catalyst Pharmaceuticals filings provide 16 years of Total Non-Current Liabilities readings, the most recent being $134.6 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 17.76% to $134.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $134.6 million, a 17.76% increase, with the full-year FY2025 number at $149.5 million, up 21.09% from a year prior.
  • Total Non-Current Liabilities hit $134.6 million in Q1 2026 for Catalyst Pharmaceuticals, down from $149.5 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $149.5 million in Q4 2025 to a low of $48.3 million in Q3 2022.
  • Median Total Non-Current Liabilities over the past 5 years was $95.3 million (2024), compared with a mean of $94.7 million.
  • Biggest five-year swings in Total Non-Current Liabilities: surged 97.52% in 2022 and later rose 17.76% in 2026.
  • Catalyst Pharmaceuticals' Total Non-Current Liabilities stood at $61.1 million in 2022, then increased by 29.61% to $79.3 million in 2023, then soared by 55.79% to $123.5 million in 2024, then grew by 21.09% to $149.5 million in 2025, then decreased by 9.95% to $134.6 million in 2026.
  • The last three reported values for Total Non-Current Liabilities were $134.6 million (Q1 2026), $149.5 million (Q4 2025), and $131.2 million (Q3 2025) per Business Quant data.